It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients
after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to
receive 3 cycles of RICE as salvage therapy.
After treatment each patient should be followed up for 2 years.